Osteoprotektion beim Mammakarzinom

Eine antiresorptive Therapie mit Bisphosphonaten oder dem Antikörper Denosumab – sog. bone modifying agents – kann das Risiko für eine Osteoporose sowie auch für die Bildung von Knochenmetastasen bei Brustkrebspatientinnen reduzieren.

• Literatur

• 1 Dougall WC. Molecular Pathways: Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL/RANK/OPG Pathway in Tumorigenesis and Metastasis. Clin Cancer Res 2011; 18: 1-10
• 2 Theriault RL. et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17: 846-854
• 3 Body JJ. et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004; 90: 1133-1137
• 4 Rosen LS. et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 1735-1744
• 5 Barrett-Lee P. et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol 2014; 15: 114-122
• 6 http://www.ago-online.de/de/infothek-fuer-aerzte/leitlinienempfehlungen/mamma/
• 7 Cummings SR. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765
• 8 Gnant M. et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 2015; 26: 313-320
• 9 Coleman R. et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO- FAST study): final 60-month results. Ann Oncol 2013; 24: 398-405
• 10 Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015; 386: 1353-1361
• 11 AGO, Kommission Mamma. Bisphosphonate und RANKL-Antikörper Denosumab. In: AGO. Diagnostik und Therapie primärer und metastasierter Mammakarzinome 2015 www.ago-online.de
• 12 Gnant M. et al. Adjuvant denosumab in breast cancer (ABSCG-18): a multicenter, randomized, double-blind, placebo-controlled trial. Lancet 2015; 386: 433-443
• 13 Ibrahim MF. et al. Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis. Ann Oncol 2015; 26: 2205-2213
• 14 www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Supportivtherapie/LL_Supportiv_Langversion_1.1.pdf